$0.200
-0.067 (-33.41%)Al cierre
- High
- 0.319
- Open
- 0.282
- VWAP
- 0.24
- Vol
- 3.85M
- Mkt Cap
- 23.17M
- Low
- 0.200
- Amount
- 922.01K
- EV/EBITDA, TTM
- -0.62
UNITY Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. It has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an a-Klotho hormone drug candidate, is being researched for multiple neurology indications.
Analyst Ratings (3)
H.C. Wainwright
$2
2025-05-27
H.C. Wainwright
2025-05-27
Precio objetivo
$2
Mizuho
$1
2025-05-16
Mizuho
2025-05-16
Precio objetivo
$1
HC Wainwright & Co.
$4
2025-04-23
HC Wainwright & Co.
2025-04-23
Precio objetivo
$4
Chardan Capital
$4
2025-04-23
Chardan Capital
2025-04-23
Precio objetivo
$4
HC Wainwright & Co.
$4
2025-03-25
HC Wainwright & Co.
2025-03-25
Precio objetivo
$4
Métricas de valoración
Cronología de eventos
Noticias
4.507-02BenzingaUS Stocks Likely To Open Higher: S&P 500 Sees 'Average Gain Of 6.1%' In 2nd Half, Expert Says
4.005-27BenzingaPTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday
4.005-27BenzingaThis United States Steel Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
4.005-27BenzingaHC Wainwright & Co. Downgrades Unity Biotechnology to Neutral, Lowers Price Target to $2
- 4.004-23Benzinga
HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $4 Price Target
UBX FAQ — answered by Alphio AI
UNITY Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. It has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an a-Klotho hormone drug candidate, is being researched for multiple neurology indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
3 analysts cover UBX: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 1.50.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.